Latest / Investor Exchange / Meta Health Admits Going Concern Risk After Q3 2025

Transcript

Meta Health Admits Going Concern Risk After Q3 2025 · Investor Exchange

• 0:02
  Time for another Investor Exchange podcast. Here are your hosts, Matt and Sally.
• 0:08
  Welcome to the Deep Dive. Today, we are cracking open a financial statement
• 0:13
  that is just one of the most astonishing paradoxes I think I've ever seen. It really is.
• 0:17
  We're looking at a company with astronomical, I mean, triple digit revenue growth,
• 0:21
  the kind of numbers that should send a stock to the moon.
• 0:24
  That phenomenal number is sitting right next to, well, continued and substantial losses.
• 0:30
  And most critically, a formal material uncertainty about whether the company
• 0:35
  can even stay in business.
• 0:37
  And that's the tightrope walk, isn't it? We're dissecting the Q3 and nine month
• 0:41
  results for MetaHealth Limited. They're in the health care space,
• 0:44
  telemedicine, nursing, that sort of thing.
• 0:46
  Right. So our mission today is to really get into that tension.
• 0:49
  We need to analyze the core numbers, figure out what's driving these dramatic
• 0:52
  shifts, and then assess how management is trying to navigate this,
• 0:56
  well, this existential crisis.
• 0:58
  And we have to start by stressing the context for you.
• 1:01
  MetaHealth is reporting under special SGX-ST rules, and that's because their
• 1:05
  last audit flagged a material uncertainty related to going concern.
• 1:09
  And what does that actually mean in plain English? It means the auditors,
• 1:13
  the professionals looking at the books, are publicly stating they have significant
• 1:16
  doubts the business will even be around in a year's time. It's the biggest red flag you can get.
• 1:22
  Okay, so that frames everything. It's a race against the clock.
• 1:24
  So let's start with the good news.
• 1:26
  The headline figure, that revenue spike. The numbers are pretty wild.
• 1:30
  For Q3, revenue from continuing operations.
• 1:34
  It jumped from just $11,000 in 2024 to $346,000 in 2025.
• 1:41
  That's a 3045% increase. 3,000%. And it's not just a one-quarter blip.
• 1:46
  The nine-month numbers are huge, too.
• 1:48
  From $100,000 in the prior year to over a million dollars in 9M 2025,
• 1:52
  that's a 920% jump. I just, I can't square these two things.
• 1:57
  How do you have 3,000% growth and a survival warning in the same report?
• 2:00
  I mean, this growth didn't come from some massive wave of new customers signing up, did it?
• 2:05
  No, not at all. And that's the absolute key to this whole story.
• 2:08
  This growth is almost entirely attributable to one thing, the revenue from their
• 2:12
  newly acquired business, Jez Medical Screening Center.
• 2:14
  Ah, so they bought it. They bought it in November 2024.
• 2:18
  This is growth by acquisition, not organic growth. A crucial, crucial detail.
• 2:24
  So you buy revenue, you get the big percentage. But then let's talk about the
• 2:27
  other side of that coin, the collapse and what they call other income,
• 2:30
  which really complicates the picture.
• 2:32
  Right. This is where it gets messy, because in the nine month period,
• 2:36
  other income just plummeted.
• 2:38
  It went from S1.1 million dollars down to just $40,000.
• 2:43
  A million dollar drop. Why? Because that S1.1 million dollars from the previous
• 2:47
  year, 9M 2024, it included a massive one off windfall. A million dollars of
• 2:53
  it was from the recovery of losses from some irregularities at a subsidiary. A windfall.
• 2:58
  So last year's numbers looked healthier because they basically got money back
• 3:01
  that they had previously lost.
• 3:02
  Exactly. So what they've done is they've swapped a one-time zero-cost financial
• 3:07
  recovery for actual operational revenue from an acquisition.
• 3:10
  Revenue that, you know, comes with a lot of costs attached.
• 3:13
  And that leads us straight to the next paradox, doesn't it? The bottom line
• 3:15
  got worse. It got much worse.
• 3:17
  Despite all that top-line growth, the group's total loss for the period actually increased.
• 3:22
  The Q3 loss was $417,000, up 14%. And the nine-month loss,
• 3:29
  It ballooned to over a million dollars. That's a 48% bigger loss than the year before.
• 3:34
  So the new expenses completely swamped the new revenue. Where did all that money
• 3:38
  go? Well, this is it. You can trace most of it right back to the Jazz Medical deal.
• 3:42
  The biggest jump by far was an employee benefits expense.
• 3:45
  How big a jump? It nearly doubled, from around $600,000 to $1.4 million.
• 3:50
  Wow, an extra $800,000 in nine months. And that's a mix of things.
• 3:54
  You've got the headcount from Jazz Medical staff, which you'd expect,
• 3:57
  But there's also a very interesting detail in there. Which is?
• 4:00
  A huge chunk of that is an accrual for a performance-based bonus for the former CEO.
• 4:05
  Okay, and the sources say this bonus is being paid out in new shares,
• 4:08
  right? Yeah. So what does that mean for existing shareholders? It means dilution.
• 4:12
  Every time they issue a new share to pay someone, your piece of the pie gets a little bit smaller.
• 4:16
  It saves them cash, which they desperately need, but it's not a free lunch for the owners.
• 4:21
  Right, so that's people costs. What about property?
• 4:24
  I see a line here for depreciation. Yep, that doubled too.
• 4:27
  It's small numbers from S$23,000 to S$36,000, but it tells the same story.
• 4:33
  They didn't buy the buildings Jazz Medical operates from, they inherited the leases.
• 4:37
  So now they have to account for those right of use assets on the balance sheet.
• 4:41
  People and property, all stemming from the acquisition.
• 4:44
  But to be fair, it looks like they did try to cut costs elsewhere.
• 4:48
  Other operating expenses went down. They did. And this is actually a pretty
• 4:52
  successful bit of housekeeping.
• 4:53
  They cut those other expenses from $700,000 down to $400,000. How'd they manage that?
• 5:00
  Two main things. First, the one-off
• 5:02
  legal and professional fees from the acquisition itself, those are gone.
• 5:06
  And second, they shut down another subsidiary, TS Medical, which saved some money.
• 5:10
  They even managed to cut their finance costs by repaying some bank loans. So...
• 5:15
  Let me get this straight. They cut $300,000 in one-off fees and other costs,
• 5:20
  but the new costs from the acquisition, just the employee part, rose by $800,000.
• 5:26
  Exactly. So this isn't really a cost control success story.
• 5:30
  It's a story where the cost of their growth strategy just completely overwhelmed
• 5:34
  their internal efficiency efforts.
• 5:35
  You've nailed it. They took two steps forward on revenue, but three steps back
• 5:39
  on profit, which brings us right back to the most serious issue here. The going concern.
• 5:44
  Let's revisit just how fragile their balance sheet was at the end of September.
• 5:48
  The numbers are stark. Net liabilities of S1.2 million dollars.
• 5:53
  And even more pressing, net current liabilities of S1.4 million dollars.
• 5:57
  And that net current liability figure, that's the one that keeps CFOs up at night.
• 6:00
  It means the bills due within the next year are S1.4 million dollars more than
• 6:04
  all the liquid assets they have to pay them. A huge immediate shortfall.
• 6:08
  And on of that, they burned through another S1.1 million dollars in cash just
• 6:12
  running the business in those nine months. A consistent, painful cash burn.
• 6:16
  So if they're burning cash and their immediate bills are bigger than their cash
• 6:22
  pile, how are they still operating? How are the lights still on?
• 6:26
  Financing. That's the only answer. They generated a net S1.0 million dollars
• 6:31
  from financing activities.
• 6:32
  That was their lifeline. Where did that million dollars come from?
• 6:35
  Two main places. They raised $1.5 million by doing a rights issue,
• 6:40
  basically going back to their existing shareholders and asking for more money.
• 6:44
  And they took on another S, $800,000 in new loans.
• 6:48
  Now, they used a big chump of that to pay down older, more expensive debt, which is smart.
• 6:53
  But fundamentally, they survived by asking for more cash and taking on new debt. Which is...
• 6:59
  Not a sustainable business model. So what are they telling the auditors to justify
• 7:03
  preparing these accounts on a going concern basis?
• 7:06
  What's the plan? They're pointing to four specific things. First,
• 7:09
  they say they're implementing serious cost-cutting strategies.
• 7:11
  Right. Trying to stem the bleeding.
• 7:13
  What else? Second, they managed to negotiate a new extended payment plan with
• 7:17
  the Royal Malaysian Customs Department for a big tax bill. So they've bought themselves some time.
• 7:21
  Okay. That's a big deal. Third, they got a little bit of cash in from that settlement
• 7:25
  we mentioned earlier with some former associates.
• 7:27
  Not a lot, but every bit helps. The first payment was received.
• 7:31
  But all of this, it feels like patching holes in a sinking boat.
• 7:35
  There must be something bigger holding it all together. There is.
• 7:38
  And this is the fourth and most important premise.
• 7:40
  The entire thing is currently anchored by a formal, written undertaking from
• 7:44
  a controlling shareholder.
• 7:46
  A kind of undertaking. A promise to provide whatever financial support is needed
• 7:50
  to meet the company's liabilities and operating expenses for 12 months,
• 7:55
  starting from April 2025.
• 7:57
  So this entire company is solvent today, not because of its operations,
• 8:02
  but because one wealthy individual has guaranteed its survival for the next
• 8:06
  year. That's it. That is the safety net.
• 8:08
  And it puts a very clear deadline on their turnaround efforts,
• 8:12
  which brings us to their strategy for the future.
• 8:14
  How do they plan to get off this lifeline?
• 8:17
  Well, their strategy seems counterintuitive given the cash crunch.
• 8:21
  Yeah. They're actively looking for more acquisition targets.
• 8:24
  Right. It's a high risk approach. They're looking at the current macroeconomic
• 8:29
  uncertainty and seeing it as a chance to buy, quote, quality assets at reasonable valuations.
• 8:35
  But if you have more immediate debts than cash, why on earth would you go shopping
• 8:40
  for more companies to buy? That requires cash.
• 8:43
  Because their gamble is that relying on slow organic growth from their existing
• 8:49
  business won't be fast enough to outrun the cash burn.
• 8:52
  They're betting they can find an acquisition that is immediately profitable
• 8:55
  and can generate the cash they need to solve their problems. A very, very big bet.
• 9:00
  And meanwhile, they still have to actually run the business they have,
• 9:03
  which they admit is facing some serious headwinds. Exactly.
• 9:06
  They mentioned stiffening competition in the local market and,
• 9:09
  critically, customers being very cautious with their spending because of inflation.
• 9:13
  So it's a tough environment to operate in. So their operational plan is all
• 9:16
  about cost control, squeezing every bit of efficiency they can out of the assets they already own.
• 9:22
  Yes. Things like switching suppliers, changing service providers,
• 9:26
  anything to improve the operating leverage on that new revenue from Jazz Medical,
• 9:30
  they have to make every dollar of revenue more profitable.
• 9:33
  So let's bring this full circle. We have MetaHealth, a company with a mind-blowing
• 9:38
  30-45% revenue growth achieved through a very expensive acquisition.
• 9:44
  But that growth led to even bigger losses.
• 9:47
  And the core conclusion is pretty stark. The company is only here today because
• 9:50
  of one-off financing, like that rights issue, and critically,
• 9:53
  that 12-month promise of support from a major shareholder.
• 9:57
  The clock is ticking on that promise.
• 9:59
  The question isn't whether they can buy revenue they've proven they can.
• 10:03
  The question is whether they can turn that revenue into actual cash.
• 10:06
  And that really leads to the final thought for you, the listener.
• 10:09
  When a company is so reliant on these temporary lifelines, how sustainable is
• 10:13
  a strategy of seeking more acquisitions? you know, while also battling fierce
• 10:18
  competition and burning through cash.
• 10:20
  Is this a high-speed turnaround or are they just delaying the inevitable?
• 10:23
  A fascinating and frankly nerve-wracking deep dive into MetaHealth's Financial Tightrope Act.
• 10:29
  Thanks for joining us to unpack these numbers. We encourage you to really think
• 10:32
  about that interplay between rapid acquisition-fueled growth and those immediate
• 10:37
  critical liquidity challenges. Thank you.